1-2 of 2
Anne M. Wolka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study

David Russell-Jones, MD, Robert M. Cuddihy, MD, Markolf Hanefeld, MD, Ajay Kumar, MD, Jose G. González, MD, Melanie Chan, PHD, Anne M. Wolka, PHD, Marilyn K. Boardman, PHARMD, on behalf of the DURATION-4 Study Group
Journal: Diabetes Care
Diabetes Care 2012;35(2):252–258
https://doi.org/10.2337/dc11-1107
Published: 16 January 2012
View article titled, Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): <subtitle>A 26-week double-blind study</subtitle>
Open the PDF for Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): <subtitle>A 26-week double-blind study</subtitle> in another window
Includes: Supplementary data
Journal Articles

A 6-Month, Randomized, Double-Masked, Placebo-Controlled Study Evaluating the Effects of the Protein Kinase C-β Inhibitor Ruboxistaurin on Skin Microvascular Blood Flow and Other Measures of Diabetic Peripheral Neuropathy

Carolina M. Casellini, MD, Patricia M. Barlow, BSN, Amanda L. Rice, BS, Melissa Casey, BS, Kathryn Simmons, BS, Gary Pittenger, PHD, Edward J. Bastyr, III, MD, Anne M. Wolka, PHD, Aaron I. Vinik, MD, PHD
Journal: Diabetes Care
Diabetes Care 2007;30(4):896–902
https://doi.org/10.2337/dc06-1699
Published: 01 April 2007
View article titled, A 6-Month, Randomized, Double-Masked, Placebo-Controlled Study Evaluating the Effects of the Protein Kinase C-β Inhibitor Ruboxistaurin on Skin Microvascular Blood Flow and Other Measures of Diabetic Peripheral Neuropathy
Open the PDF for A 6-Month, Randomized, Double-Masked, Placebo-Controlled Study Evaluating the Effects of the Protein Kinase C-β Inhibitor Ruboxistaurin on Skin Microvascular Blood Flow and Other Measures of Diabetic Peripheral Neuropathy in another window